Merck Slips 4.4% After Q3 as Analyst Upgrades Collide With Peer Underperformance
MRK closed Tuesday at $141.82, down 4.4% on the week, while its closest pharmaceutical peers gained a median 1.7% over the same period. JNJ added 3.6%, RPRX rose 4.9%, and even LLY and BMY were roughly flat. The Q3…